Evidence map›Paper›PMID 32019188›Full record

ArticleInternational journal of molecular sciences2020

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)

Tristan M Sissung, Roberto H Barbier, Douglas K Price, Teri M Plona, Kristen M Pike, Stephanie D Mellott, Ryan N Baugher, Gordon R Whiteley, Daniel R Soppet, David Venzon and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. UGT1A1 Fragment Analysis: Genotyping the (TA)Journal of clinical laboratory analysis · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genotyping ofPharmaceutics · 2022
    Article
  8. Article
  9. Genes · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Tristan M SissungClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Roberto H BarbierMolecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Douglas K PriceMolecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Teri M PlonaCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
Kristen M PikeCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
Stephanie D MellottCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
Ryan N BaugherCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
Gordon R WhiteleyCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.ORCID 0000-0001-7898-6269
Daniel R SoppetGenomics Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.
David VenzonBiostatistics and Data Management, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA.ORCID 0000-0002-8990-158X
Arlene BermanOffice of Research Nursing in the Office of the Clinical Director, National Cancer Institutes, National Institutes of Health, Bethesda, MD 20892, USA.
Arun RajanThoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Giuseppe GiacconeDepartment of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Paul MeltzerGenetics Branch, National Cancer Institute, Bethesda, MD 20814, USA.
William D FiggClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USLeidos (United States) · USCornell University · USNational Cancer Institute · US

Funding

CCR Research NursingZIDBC011716 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KARZAI, FATIMA · 2016 to 2025
$216.6M
Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$13.9M
Anti-PD-L1-TGFb antibody (M7824) in advanced Non-Small Cell Lung CancerZIABC011905 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI RAJAN, ARUN · 2019 to 2025
$817k
NIH HHS ZIA BC 010627
6 · The paper itself

Abstract

To ensure accuracy of

Indexed as

Polymorphism, GeneticAllelesGenotypeGenotyping TechniquesGlucuronosyltransferaseHumansIrinotecanPharmacogeneticsPolymerase Chain ReactionUGT1A1 EnzymeGlucuronosyltransferaseIrinotecanUGT1A1 EnzymepharmacogenomicsUGT1A1

Identifiers

PMID32019188
PMCPMC7037496
OpenAlexW3003862628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.